As part of their RAMP experience, Scholars may have the opportunity to contribute to scholarly presentations and manuscripts as lead or contributing authors. Below are publications resulting from RAMP Scholar projects.

20232022  |  2020  |  2019  |  2018  |  2017  |  2016  |  2015  |  2014


Grant W, Adan MA, Samurkas CA, Quigee D, Benitez J, Gray B, Carnevale C, Gordon RJ, Castor D, Zucker J, Sobieszczyk ME. Effect of Participative Web-Based Educational Modules on HIV and Sexually Transmitted Infection Prevention Competency Among Medical Students: Single-Arm Interventional Study. JMIR Med Educ. 2023 Jan 24;9:e42197. doi: 10.2196/42197. PMID: 36692921; PMCID: PMC9906317.


Asare K, Andine T, Naicker N, Dorward J, Singh N, Spooner E, Andriesen J, Osman F, Ngcapu S, Vandormael A, Mindel A, Abdool Karim SS, Bekker LG, Gray G, Corey L, Tomita A, Garrett N. Impact of point-of-care testing on the management of sexually transmitted infections in South Africa: Evidence from the HVTN702 HIV vaccine trial. Clin Infect Dis. 2022 Oct 15:ciac824. doi: 10.1093/cid/ciac824. Epub ahead of print. Erratum in: Clin Infect Dis. 2022 Dec 01;: PMID: 36250382.

Malahleha, M., Dilraj, A., Jean, J., Morar, N., Dietrich, J., Ross, M., Mbatsane, E., Keefer, M., & Ahmed, K. (2022). Exploring a community’s understanding of HIV vaccine‑induced seropositivity in a South African research setting. South African Medical Journal, 113(1), 36–41.

Fatola, O., Corneli, A., Perry, B., Hanlen-Rosado, E., Nsonwu, A., Constantine, E. P., & Thompson, A. B. (2022). "An Extra Variable to Consider"-Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical Trials. Journal of the Pediatric Infectious Diseases Society, piac001. Advance online publication.


Adan M, Zucker J, Carnevale C, Grant W, Cohall A, Gordon P, Olender S, Sobieszczyk ME.  Clinical and Demographic Characteristics of HIV Post-Exposure Prophylaxis Users in New York City. J Health Care Poor Underserved. May 2020; 31 (2):  672-681.

Oganezova, K., Fontana-Martinez, E. J., Gothing, J. A., Pandit, A., Kwara, E., Yanosick, K., Dragavon, J., Goecker, E. A., Maenza, J., Espy, N., Tomaka, F., Lavreys, L., Allen, M., D'Souza, P., Hural, J., Coombs, R. W., Dolin, R., Seaman, M. S., Walsh, S. R., & Baden, L. R. (2020). Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees. Open forum infectious diseases, 8(1), ofaa606.

Taylor NK, Young MR, Williams VD, Benitez J, Usher D, Hammer SM, Tieu HV, Sobieszczyk ME. Assessing Knowledge of HIV Vaccines and Biomedical Prevention Methods Among Transgender Women in the New York City Tri-State Area. Transgend Health. 2020 Jun 8;5(2):116-121.


LaBranche CL, Henderson R, Hsu A, Behrens S, Chen X, Zhou T, Wiehe K,  Saunders KO, Alam SM, Bonsignori M, Borgnia MJ, Sattentau QJ, Eaton A, Greene K, Gao H, Liao H-X, Williams WB, Peacock J, Tang H, Perez LG, Edwards RJ, Kepler TB, Korber BT, Kwong PD, Mascola JR, Acharya P, Haynes BF, Montefiori DC. Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancester of CH235 lineage CD4bs broadly neutralizing antibodies. PLoS Pathog 2019; 15(9): e1008026.


LaBranche CC, McGuire AT, Gray MD, Behrens S, Kwong PDK, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Chen X, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. PLoS Pathog. 2018 Nov 5;14(11):e1007431.  

Behrens S, LaBranche CC, Zhou T, Wiehe K, Bonsignori M, Sattentau QJ, Eaton A, Greene K, Gao H, Williams WB, Saunders K, Perez LG, Korber BT, Kwong PD, Mascola JR, McGuire AT, Stamatatos L, Acharya P, Haynes BF, Montefiori DC. Germline-Targeting and Reverse Engineering to Elicit CH235.12 Lineage BNAbs. Poster Presentation, HIVR4P, Madrid, Spain, October 21-25, 2018.

Thiam-Diouf A, Metch B, Sharpe C, Mulugeta R, Andrasik MP.  Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention. Vaccine. 2018 Feb 21;36(9):1235-1242.


Musuruana M, Koblin B, Lucy D, Ortiz G, McCrossin J, Usher D, Tieu HV. A pilot study comparing sexual risk data collected via smartphone app diaries and online survey questionnaire among at-risk HIV negative men who have sex with men. Poster Presentation, IAS 2017, Paris, France, July 23-26, 2017

Richardson S, Seekaew P, Koblin B, Vazquez T, Nandi V, Tieu HV. Barriers and facilitators of HIV vaccine and prevention study participation among Young Black MSM and transwomen in New York City. PLoS One. 2017 Jul 19;12(7):e0181702.

Van Tieu H, Lemos M, Andrasik M, Fleming I, Nandi V, Ortiz G, Lucy D, Musuruana M, McElrath MJ, Koblin BA. Acceptability of self-collected rectal swabs for HIV exposure testing among MSM/TGW. Poster Presentation, CROI 2017, Seattle, WA, USA, February 13-16, 2017


Marte S, Williams VD, Benitez J, McCrossin J, Usher D, Hammer S, Koblin B, Tieu HV, Sobieszczyk ME. Engaging Transgender Men in Biomedical HIV Prevention Research in New York City. Poster Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

Wallace S, Andrasik M, Chong N, Johnson S, Gaither-Hardy D, Wahl L, Okolo V, Humes D. A Qualitative Examination of Attitudes and Perceptions of HIV Clinical Research among Historically Black College and University Faculty and Students. Poster Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

Piepenbrink MS, Samuel M, Zheng B, Carter B, Fucile C, Bunce C, Kiebala M, Khan AA, Thakar J, Maggirwar SB, Morse D, Rosenberg AF, Haughey NJ, Valenti W, Keefer MC, Kobie JJ. Humoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin Users. PLoS One. 2016 Jul 5;11(7):e0158641.

Nicholas KJ, Greenplate AR, Flaherty DK, Matlock BK, Juan JS, Smith RM, Irish JM, Kalams SA. Multiparameter analysis of stimulated human peripheral blood mononuclear cells: A comparison of mass and fluorescence cytometry. Cytometry A. 2016 Mar;89(3):271-80


Carpenter C, Sidney J, Kolla R, Nayak K, Tomiyama H, Tomiyama C, Padilla OA, Rozot V, Ahamed SF, Ponte C, Rolla V, Antas PR, Chandele A, Kenneth J, Laxmi S, Makgotlho E, Vanini V, Ippolito G, Kazanova AS, Panteleev AV, Hanekom W, Mayanja-Kizza H, Lewinsohn D, Saito M, McElrath MJ, Boom WH, Goletti D, Gilman R, Lyadova IV, Scriba TJ, Kallas EG, Murali-Krishna K, Sette A, Lindestam Arlehamn CS. A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. Tuberculosis (Edinb). 2015 Dec;95(6):713-721

Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, Liu P, Tay MZ, Seaton KE, Shen X, Foulger A, Lloyd KE, Parks R, Pollara J, Ferrari G, Yu JS, Vandergrift N, Montefiori DC, Sobieszczyk ME, Hammer S, Karuna S, Gilbert P, Grove D, Grunenberg N, McElrath MJ, Mascola JR, Koup RA, Corey L, Nabel GJ, Morgan C, Churchyard G, Maenza J, Keefer M, Graham BS, Baden LR, Tomaras GD, Haynes BF. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science. 2015 Aug 14;349(6249):aab1253.


Teigler JE, Penaloza-MacMaster P, Obeng R, Provine NM, Larocca RA, Borducchi EN, Barouch DH. Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors. Clin Vaccine Immunol. 2014 Aug;21(8):1137-44.

Coombs A, McFarland W, Ick T, Fuqua V, Buchbinder SP, Fuchs JD. Long-chain peer referral to recruit black MSM and black transgender women for an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):e94-7.